Back
 JCT  Vol.1 No.1 , March 2010
Sum-Based Meta-Analytical Enrichment of Gene Expression Data to Identify Pathway Signatures of Cancers
Abstract: A new method for analysis of microarray gene expression experiments referred to as Sum-based Meta-analytical Enrichment (SME) is proposed in this manuscript. SME is a combined enrichment and meta-analytical approach to infer on the association of gene sets with particular phenotypes. SME allows enrichment to be performed across datasets, which to our knowledge was not earlier possible. As a proof of concept study, this technique is applied to datasets from Oncomine, a publicly available cancer microarray database. The genes that are significantly up-/down-regulated (p-value ≤ 10-4) in various cancer types in Oncomine were listed. These genes were assigned to biological processes using GO annotations. The SME algorithm was applied to identify a list of GO processes most deregulated in 4 major cancer types. For validation we examined whether the processes predicted by SME were already documented in literature.SME method identified several known processes for the 4 cancer types and identified several novel processes which are biologically plausible. Nearly all the pathways identified by SME as common to the 4 cancers were found to contribute to processes which are widely regarded as cancer hallmarks. SME provides an intuitive yet objective ‘process-centric’ interpretation of the ‘gene-centric’ output of individual microarray comparison studies. The methods described here should be applicable in the next-generation sequencing based gene expression analysis as well.
Cite this paper: K. Wagholikar, P. Venkatraman, S. Vijayraghavan and C. Kumar-Sinha, "Sum-Based Meta-Analytical Enrichment of Gene Expression Data to Identify Pathway Signatures of Cancers," Journal of Cancer Therapy, Vol. 1 No. 1, 2010, pp. 36-42. doi: 10.4236/jct.2010.11006.
References

[1]   D. R. Rhodes and A. M. Chinnaiyan, “Integrative analysis of the cancer transcriptome,” Nature Genetics, supplement Vol. 37, pp. S31–S37, 2005.

[2]   A. A. Alizadeh, et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, Vol. 403, No. 6769, pp. 503–511, 2000.

[3]   L. J. van 't Veer, et al., “Gene expression profiling predicts clinical outcome of breast cancer,” Nature, Vol. 415, No. 6871, pp. 530–536, 2002.

[4]   D. R. Rhodes, et al., “Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression,” Proceedings of the National Academy of Science, U S A, Vol. 101, No. 25, pp. 9309–9314, 2004.

[5]   P. Khatri and S. Draghici, “Ontological analysis of gene expression data: Current tools, limitations, and open problems,” Bioinformatics, Vol. 21, No. 18, pp. 3587– 3595, 2005.

[6]   J. J. Goeman, et al., “A global test for groups of genes: Testing association with a clinical outcome,” Bioinformatics, Vol. 20, No. 1, pp. 93–99, 2004.

[7]   P. Pavlidis, et al., “Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex,” Neurochemical Research, Vol. 29, No. 6, pp. 1213–1222, 2004.

[8]   V. K. Mootha, et al., “PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down regulated in human diabetes,” Nature Genetics, Vol. 34, No. 3, pp. 267–273, 2003.

[9]   A. Subramanian, et al., “From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Science, U S A, Vol. 102, No. 43, pp. 15545–15550, 2005.

[10]   R. Barriot, D. J. Sherman, and I. Dutour, “How to decide which are the most pertinent overly-represented features during gene set enrichment analysis,” BMC Bioinformatics, Vol. 8, pp. 332, 2007.

[11]   G. S. Eichler, et al., “The LeFE algorithm: Embracing the complexity of gene expression in the interpretation of microarray data,” Genome Biology, Vol. 8, No. 9, pp. R187, 2007.

[12]   Z. Wei and H. Li, “Nonparametric pathway-based regression models for analysis of genomic data,” Biostatistics, Vol. 8, No. 2, pp. 265-284, 2007.

[13]   S. Draghici, et al., “A systems biology approach for pathway level analysis,” Genome Research, Vol. 17, No. 10, pp. 1537–1545, 2007.

[14]   D. R. Rhodes, et al., “Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles,” Neoplasia, Vol. 9, No. 2, pp. 166–180, 2007.

[15]   J. Quackenbush, “Computational analysis of microarray data,” Nature Reviews Genetics, Vol. 2, No. 6, pp. 418– 427, 2001.

[16]   D. Stekel, Microarray Bioinforamtics, Cambridge University Press, Cambridge, 2003.

[17]   Oncomine, Available from: http://www.oncomine.org. 2007.

[18]   M. A. Harris, et al., “The Gene Ontology database and informatics resource,” Nucleic Acids Research, Vol. 32 (Database issue), pp. D258–D261, 2004.

[19]   Y. Komada and M. Sakurai, “Shedding of CD9 antigen in acute lymphoblastic leukemia,” Leukemia and Lymphoma, Vol. 12, No. 5-6, pp. 365–372, 1994.

[20]   C. Ricci, F. Onida, and R. Ghidoni, “Sphingolipid players in the leukemia arena,” Biochimica et Biophysica Acta, Vol. 1758, No. 12, pp. 2121–2132, 2006.

[21]   R. Huang, A. Wallqvist, and D. G. Covell, “Targeting changes in cancer: Assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues,” Molecular Cancer Therapeutics, Vol. 5, No. 9, pp. 2417–2427, 2006.

[22]   H. Kulbe, et al., “The chemokine network in cancer--much more than directing cell movement,” International Journal of Developmental Biology, Vol. 48, No. 5-6, pp. 489–496, 2004.

[23]   J. Meijer, et al., “The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver,” Cancer Research, Vol. 66, No. 19, pp. 9576–9582, 2006.

[24]   G. Opdenakker and J. Van Damme, “The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines,” International Journal of Developmental Biology, Vol. 48, No. 5-6, pp. 519–527, 2004.

[25]   J. L. Lauer-Fields, D. Juska, and G. B. Fields, “Matrix metalloproteinases and collagen catabolism,” Biopolymers, Vol. 66, No. 1, pp. 19–32, 2002.

[26]   A. E. Kossakowska, S. J. Urbanski, and A. Janowska-Wieczorek, “Matrix metalloproteinases and their tissue inhibitors-expression, role and regulation in human malignant non-Hodgkin's lymphomas,” Leukemia and Lymphoma, Vol. 39, No. 5–6, pp. 485–493, 2000.

[27]   Y. Tang, et al., “Role of Rho GTPases in breast cancer,” Frontiers in Bioscience, Vol. 13, pp. 759–776, 2008.

[28]   J. S. Ross, et al., “The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine,” Oncologist, Vol. 14, No. 4, pp. 320–368, 2009.

[29]   M. L. Zhu and N. Kyprianou, “Androgen receptor and growth factor signaling cross-talk in prostate cancer cells,” Endocrine-Related Cancer, Vol. 15, No. 4, pp. 841 –849, 2008.

[30]   S. Varambally, et al., “Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression,” Cancer Cell, Vol. 8, No. 5, pp. 393– 406, 2005.

[31]   D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, Vol. 100, No. 1, pp. 57–70, 2000.

[32]   A. C. Pfeifer, J. Timmer and U. Klingmuller, “Systems biology of JAK/STAT signaling,” Essays in Biochemistry, Vol. 45, pp. 109–120, 2008.

[33]   J. T. Durham and I. M. Herman, “Systems biology of JAK/STAT signalling: Inhibition of angiogenesis in vitro: a central role for beta-actin dependent cytoskeletal remodeling,” Microvascular Research, Vol. 45, No. 3, pp. 109–120, 2008.

[34]   J. M. Argilés, et al., “Catabolic mediators as targets for cancer cachexia,” Drug Discovery Today, Vol. 8, No. 18, pp. 838–844. 2003.

[35]   S. Cheng and S. Balk, Steroid Hormone Receptor Signaling in Cancer.

 
 
Top